What Researchers Did
Researchers conducted a comprehensive review of publications from 1946 to the present to provide evidence-based treatment guidance for mucormycosis complicating burns.
What They Found
The review identified 151 cases of mucormycosis complicating burns, reporting a mortality rate of 54.5%, which significantly increased with axial body site involvement. Prompt radical debridement was the standard treatment, and while no systemic treatment reached statistical significance, amphotericin B trended toward significance, leading to recommendations for its use with posaconazole.
What This Means for Canadian Patients
This study provides valuable evidence-based treatment guidance for a rare but highly fatal fungal infection in burn patients. Canadian burn centers could utilize these recommendations to improve diagnosis and management, potentially reducing mortality rates.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A limitation is the lack of strong statistical evidence for the efficacy of systemic treatments, suggesting a need for further robust studies.